Yuri Rivera, PA
Physician Assistant · Purvis, MSNPI 1699836791
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,242 of the $3,620 with a category attached, or 89.6%. It is spread thinly across 27 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations.
Across 197 payments — averaging $18.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$741
- Amgen$454
- Novo Nordisk$334
- Astellas Pharma US Inc$318
- Merck$182
- AbbVie$180
- plus $1K from 21 others
What the payments were for
- Consulting fees$1755%
- Food & beverage$3,24290%
- Education$2036%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 71 | $741 |
| Amgen | 17 | $454 |
| Novo Nordisk | 19 | $334 |
| Astellas Pharma US Inc | 4 | $318 |
| Merck | 9 | $182 |
| AbbVie | 12 | $180 |
| Lilly USA, LLC | 6 | $153 |
| E.r. Squibb & Sons, L.L.C. | 5 | $148 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $132 |
| AstraZeneca | 5 | $130 |
| Kowa Pharmaceuticals America, Inc. | 7 | $106 |
| GSK | 6 | $99 |
| Novartis | 5 | $97 |
| Boehringer Ingelheim | 3 | $93 |
| Phathom Pharmaceuticals, Inc. | 4 | $78 |
| Otsuka America Pharmaceutical, Inc. | 3 | $70 |
| Abbott | 3 | $48 |
| Paratek Pharmaceuticals, Inc. | 3 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $41 |
| Lundbeck LLC | 2 | $38 |
| Shield Therapeutics Inc | 2 | $35 |
| Bayer | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Exact Sciences | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,620 in reported general payments places this provider in the 80th percentile of 278 physician assistant providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 42 | $48,784 |
| EliquisApixaban | 30 | $37,582 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $37,265 |
| LinzessLinaclotide | 36 | $34,820 |
| OzempicSemaglutide | 16 | $26,099 |
| Bydureon BciseExenatide Microspheres | 15 | $14,783 |
| TrulicityDulaglutide | 13 | $13,866 |
| JanuviaSitagliptin Phosphate | 14 | $13,355 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $11,943 |
| Repatha SureclickEvolocumab | 18 | $11,359 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $10,895 |
| XareltoRivaroxaban | 13 | $10,593 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 17 | $3,922 |
| Rosuvastatin Calcium | 286 | $2,991 |
| Humalog Mix 75-25Insulin Lispro Protamin/Lispro | 13 | $2,160 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $93 | $48,78442 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $99 | $48,16046 claims |
| PfizerEliquis | $741 | $37,58230 claims |
| AbbVieLinzess, Synthroid | $180 | $35,45652 claims |
| Novo NordiskOzempic | $334 | $26,09916 claims |
| Lilly USA, LLCTrulicity, Humalog Mix 75-25 | $153 | $16,02626 claims |
| MerckJanuvia | $182 | $13,35514 claims |
| Johnson & JohnsonXarelto | $15 | $10,59313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 278 physician assistant providers in Mississippi.
Other physician assistant in Purvis
- Lavinia DrambareanHattiesburg$382K
- Karmen ClarkOcean Springs$49K
- Kristen RichardsonFlowood$21K
- Connie KlotzbachOcean Springs$20K
- Nichole HornHattiesburg$19K
- Hannah SavelyTupelo$13K
- Barry FlippoSouthaven$13K
- Mary AdamsOcean Springs$13K
- Siera ShiyouJackson$12K
- Katie McDanielOxford$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.